Tarantino, Dalia
Walker, Callum
Weekes, Daniel
Pemberton, Helen
Davidson, Kathryn
Torga, Gonzalo http://orcid.org/0000-0002-6401-5127
Frankum, Jessica
Mendes-Pereira, Ana M.
Prince, Cynthia
Ferro, Riccardo
Brough, Rachel
Pettitt, Stephen J. http://orcid.org/0000-0003-3313-3857
Lord, Christopher J. http://orcid.org/0000-0002-3226-0515
Grigoriadis, Anita http://orcid.org/0000-0003-3434-201X
NJ Tutt, Andrew http://orcid.org/0000-0001-8715-2901
Funding for this research was provided by:
King's Health Partners | Guy's and St Thomas' NHS Foundation Trust
Breast Cancer Now
King's Health Partners | Guy's and St Thomas' NHS Foundation Trust
Breast Cancer Now
King's Health Partners | Guy's and St Thomas' NHS Foundation Trust
Article History
Received: 29 July 2021
Revised: 21 May 2022
Accepted: 30 May 2022
First Online: 29 June 2022
Competing interests
: ANJT is/has been a consultant for AstraZeneca, Merck KGaA, Artios, Pfizer, Vertex, GE Healthcare, Inbiomotion, Prime Oncology, Medscape Education, EMPartners, VJ Oncology, Gilead and MD Anderson Cancer Centre; has received grant/research support from AstraZeneca, Myriad, Medivation and Merck KGaA; is a stockholder in Inbiomotion; and stands to gain from the use of PARPi as part of the Institute of Cancer Research ‘rewards to inventors’ scheme. CJL makes the following disclosures: receives and/or has received research funding from: AstraZeneca, Merck KGaA, Artios. Received consultancy, SAB membership or honoraria payments from: Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate. Has stock in: Tango, Ovibio, Enedra Tx., Hysplex, Tesselate. CJL is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR “Rewards to Inventors” scheme. The remaining authors declare no competing interests.